The CDC announced the loss of a large stock of yellow fever vaccine during a Sanofi Pasteur plant relocation and said the US-licensed vaccine will not be available again until next year. The FDA has cleared Sanofi to bring in Stamaril, a yellow fever vaccine made in France, under the investigational drug program.
A midstage study in the journal Blood found that 32% of patients treated with vorinostat prophylaxis developed
acute graft-versus-host disease in the year after hematopoietic stem cell transplantation from an 8/8 HLA-matched unrelated donor to treat a hematologic malignancy. After 30 days, levels of GVHD biomarkers were lower in patients treated with vorinostat.
A meta-analysis of 12 late-stage randomized clinical trials by Australian researchers found that the use of novel oral anticoagulants resulted in a decline in intraocular bleeding in comparison to the use of warfarin for patients with venous thromboembolism or atrial fibrillation. The study in JAMA Ophthalmology included the NOACs apixaban, dabigatran, edoxaban and rivaroxaban.
Patients with chronic lymphocytic leukemia previously treated with ibrutinib had an overall response rate of 71% to CD19-specific chimeric antigen receptor T-cell therapy, according to a study in the Journal of Clinical Oncology. In 17 of 21 patients whose bone marrow was tested with high-resolution flow cytometry, no marrow disease was detected.
More than 139,000 kidney patients in California received treatment at dialysis clinics in 2016, a 46% increase compared with eight years ago, according to the Office of Statewide Health Planning and Development. The increase has been credited to improved survival of kidney patients due to advances in treatment for infections and cardiovascular disease.
A team of researchers from the Netherlands developed a liquid biopsy called thromboSeq that identified tumor RNA in thrombocytes with nearly 90% accuracy in diagnosing non-small-cell lung cancer, according to a study in the journal Cancer Cell.
The FDA approved VBI Vaccines' investigational new drug application for its immunotherapy candidate VBI-1901, which is being developed as a treatment for patients with glioblastoma multiforme. A Phase I/IIa study of the drug is expected to be launched later this year.
Tim Anegon, who died from complications after a liver transplant, was an eye tissue donor, and his gift aided researchers studying diabetic eye disease, the leading cause of vision impairment among adults of working age. "A lot of the research being done on animal and cell models still teaches a lot, but we're missing that link in translating to the human pathology," Dr. Patrice Fort told Anegon's family during a meeting at the University of Michigan's Kellogg Eye Center.
Researchers found that the Ebola virus has the potential to replicate and spread through human retinal pigment epithelial cells, according to a study in the journal Translational Vision Science & Technology. "We speculate that infected cells activate the type 1 IFN response, which would limit spread of infection, but that these cells also restrict innate and adaptive immune responses, which otherwise would clear the virus from the eye," the study authors wrote.
Microsoft co-founder Bill Gates donated a record-breaking $4.6 billion to the Bill & Melinda Gates Foundation Monday and on Tuesday announced the launch of an anti-malaria campaign. Gates asked his blog followers to read a malaria-related post and then take a related quiz, promising to donate one mosquito bed net per participant to families in Mozambique.
- Page 1